Clinical trial

A Randomized Study Comparing the Immune Modulation Effect of Ribociclib, Palbociclib, and Abemaciclib in ER+/HER2- EBC

NCT05766410

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2022-09-16

PhasePHASE2

Study timeline

Study start (actual)2022-09-16Date precision: day

Registry last updated2023-03-16

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Breast Cancerunresolved

Hormone Receptor-positive Breast Cancerunresolved

Hormone Therapyunresolved

Interventions

PalbociclibDRUG · verified · RxNorm: palbociclib

RibociclibDRUG · verified · RxNorm: ribociclib

AbemaciclibDRUG · verified · RxNorm: abemaciclib

LetrozoleDRUG · verified · RxNorm: letrozole

Sponsors & collaborators

National Taiwan University Hospitallead sponsor

Mapped research locations

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05766410 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.